Status:
COMPLETED
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
Lead Sponsor:
UCB BIOSCIENCES, Inc.
Conditions:
Partial Epilepsies
Partial Onset Seizures
Eligibility:
All Genders
16-60 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to allow eligible subjects from the parent study, SP925 \[NCT00655551\] to continue lacosamide and to obtain additional long-term safety data
Detailed Description
A multicenter, open-label extension study to assess the long-term safety and tolerability of lacosamide as adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in th...
Eligibility Criteria
Inclusion
- Eligible subjects who participated in SP925 \[NCT00655551\] for treatment of partial-onset seizures
Exclusion
- Receiving any study drug or experimental device other than lacosamide
- Meets withdrawal criteria for parent study SP925 \[NCT00655551\]
- Experiencing ongoing serious adverse event
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT00655486
Start Date
April 1 2008
End Date
June 1 2010
Last Update
July 17 2018
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States
2
Baltimore, Maryland, United States
3
Chesterfield, Missouri, United States
4
Columbus, Ohio, United States